Delivery Order SPE2DB24D2109-SPE2DB25FHXSC
- Not listed
- The Defense Logistics Agency awarded a $3,998.11 delivery order to AmerisourceBergen Drug Corp for Mestinon 180 mg Timespan in quantities of 30 units. This is a firm fixed-price, competitively awarded contract with no set-aside designation, featuring an ultimate completion date of August 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its Corporate Office location in Conshohocken, PA 19428. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,496.72 to AmerisourceBergen Drug Corp for Mestinon 180 mg Timespan in quantities of 30 units. This firm fixed price, non-set-aside contract was awarded on August 18, 2025, with an ultimate completion date of August 19, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $9,466.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30 units of Mestinon 180 mg Timespan, a medication commonly used to treat myasthenia gravis and other neuromuscular conditions. The contract, awarded on September 12, 2025, with an ultimate completion date of September 15, 2025, was competitively awarded with no set-aside designation. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mestinon 180 mg Timespan in quantities of 30 units, valued at $4,993.44. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and was awarded on a competitive basis without set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency issued a delivery order valued at $7,166.59 to AmerisourceBergen Drug Corp for the supply of Mestinon 180 mg Timespan in quantities of 30 units. This firm fixed-price delivery order, awarded on September 11, 2025, with completion targeted for September 12, 2025, represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The award was made through open competition with no set-aside designation, and performance will be...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,367.94 firm fixed-price delivery order is for the supply of MESTINON 180 MG TIMESPAN UU 30S, a medication used to treat myasthenia gravis. The contract has an ultimate completion date of May 17, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of MESTINON 180 MG TIMESPAN UU 30S medication. The contract has a firm fixed price of $5,440.14 and a completion date of May 21, 2024. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Mestinon 180 mg Timespan tablets. The contract is a Firm Fixed Price Delivery Order valued at $1,416.87, with a period of performance through April 26, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is also registered in the System for Award Management (SAM.gov). The contract does not...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,254.70 firm fixed-price delivery order is for the supply of 4,564,960 tablets of the medication Mestinon 60 mg. The contract has an ultimate completion date of June 21, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which...
- This contract award, valued at $6,214.03, was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of MESTINON 180 MG TIMESPAN UU 30S, a pharmaceutical product. This contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- SPE2DB24D2109Indefinite Delivery Contract
- SPE2DB24D2109-SPE2DB25FHXSCDelivery Order
The Defense Logistics Agency awarded a $7,037.30 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Mestinon 180 mg Timespan in quantities of 30 units. This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of August 14, 2025. The contract is performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion prime vendor agreement valued through December 2026 that enables AmerisourceBergen to supply comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Mestinon, a medication used to treat myasthenia gravis and other neuromuscular conditions, represents the type of specialized pharmaceutical commodity the company routinely delivers through its DLA contracts. The company's extensive federal contract portfolio demonstrates its capability to meet competitive procurement requirements across a broad spectrum of therapeutic domains, ranging from specialty medications to vaccines and medical supplies supporting military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 8/13/25 |